47.69
1.32%
0.62
アフターアワーズ:
47.36
-0.33
-0.69%
前日終値:
$47.07
開ける:
$46.98
24時間の取引高:
343.85K
Relative Volume:
0.87
時価総額:
$3.06B
収益:
$88.55M
当期純損益:
$-157.85M
株価収益率:
-17.28
EPS:
-2.76
ネットキャッシュフロー:
$-137.92M
1週間 パフォーマンス:
-1.65%
1か月 パフォーマンス:
+10.75%
6か月 パフォーマンス:
+27.51%
1年 パフォーマンス:
+234.20%
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2023-06-30 | 開始されました | Truist | Buy |
2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
2022-11-08 | 開始されました | Raymond James | Mkt Perform |
2022-08-15 | 開始されました | Jefferies | Buy |
2022-08-03 | 開始されました | Goldman | Buy |
2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
2022-04-28 | 開始されました | Credit Suisse | Outperform |
2022-03-10 | 開始されました | JP Morgan | Neutral |
2022-02-10 | 開始されました | Wells Fargo | Overweight |
2021-09-30 | 開始されました | B. Riley Securities | Neutral |
2021-09-30 | 開始されました | Stifel | Buy |
2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
2021-05-21 | 開始されました | UBS | Buy |
2021-04-14 | 開始されました | Berenberg | Buy |
2020-12-04 | 開始されました | H.C. Wainwright | Buy |
2020-09-15 | 開始されました | BofA Securities | Neutral |
2020-09-15 | 開始されました | Cowen | Outperform |
2020-09-15 | 開始されました | Guggenheim | Buy |
2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times
Mirae Asset Global Investments Co. Ltd. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat
Immunology to take front seat at Kymera - The Pharma Letter
Earnings call: Kymera Therapeutics advances in immunology and oncology By Investing.com - Investing.com Australia
Earnings call: Kymera Therapeutics advances in immunology and oncology - Investing.com India
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report - Yahoo Finance
FY2024 Earnings Estimate for KYMR Issued By Leerink Partnrs - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
(KYMR) Long Term Investment Analysis - Stock Traders Daily
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus - MSN
Kymera Therapeutics (NASDAQ:KYMR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
The Latest Analyst Ratings For Kymera Therapeutics - Benzinga
Kymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from Truist Financial - MarketBeat
Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
B.Riley boosts Kymera stock target amid cautious optimism for STAT6 degrader - Investing.com Australia
Kymera Therapeutics stock target lifted by Stifel, buy rating on oncology pivot - Investing.com UK
Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift - TipRanks
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap DownTime to Sell? - MarketBeat
Kymera Therapeutics (KYMR) Q3 2024 Earnings: EPS Misses at -$0.8 - GuruFocus.com
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - StockTitan
Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To K - GuruFocus.com
Preview: Kymera Therapeutics's Earnings - Benzinga
Insights Ahead: Kymera Therapeutics's Quarterly Earnings - Benzinga
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Thursday - MarketBeat
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases - StockTitan
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 - ForexTV.com
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium - The Manila Times
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Trading 6.8% HigherStill a Buy? - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decline in Short Interest - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
SG Americas Securities LLC Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics (NASDAQ:KYMR) & Novozymes A/S (OTCMKTS:NVZMY) Critical Comparison - Defense World
How To Trade (KYMR) - Stock Traders Daily
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance - Yahoo Finance
Kymera advances novel STAT6 degrader into clinical trials - Investing.com
Kymera Therapeutics' Application for KT-621 Gets FDA Clearance - Marketscreener.com
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader - The Manila Times
Kymera advances novel STAT6 degrader into clinical trials By Investing.com - Investing.com UK
The Manufacturers Life Insurance Company Raises Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Dimensional Fund Advisors LP Buys 53,176 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors - Seeking Alpha
Algert Global LLC Purchases 4,622 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by ProShare Advisors LLC - Defense World
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):